oxonic acid has been researched along with Anorexia in 49 studies
Oxonic Acid: Antagonist of urate oxidase.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "Nausea was improved in the next morning, and the patient ate almost all of his breakfast." | 5.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| " Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)." | 5.10 | [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| "The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | 2.79 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
| "Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m(2) over 30 min on day 1, and oral S-1 at a dose of 40 mg/m(2) twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1-7, every 2 weeks." | 2.79 | A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
| " The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| "Patients with histological proof of prostate cancer refractory to hormonal therapies were eligible." | 2.75 | Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study. ( Akaza, H; Fujimoto, H; Ikemoto, I; Kobayashi, M; Naito, S; Namiki, M; Tsukamoto, T; Usami, M, 2010) |
| "We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer." | 2.72 | [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]. ( Hyodo, I, 2006) |
| "Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.72 | [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. ( Kawahara, M; Yumine, K, 2006) |
| "The incidence and mortality of pancreatic cancer has increased very rapidly in Japan." | 2.72 | [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. ( Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006) |
| " We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
| "Paclitaxel was scheduled to be given intravenously on days 1 and 8." | 2.43 | [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer]. ( Gotoh, M; Kawabe, S; Takiuchi, H, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis." | 2.43 | [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
| "The prognosis for locally advanced gastric cancer (AGC) remains unsatisfactory, even with S-1 adjuvant chemotherapy." | 1.43 | Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. ( Aizawa, M; Matsuki, A; Migita, K; Nashimoto, A; Yabusaki, H, 2016) |
| "Nausea was improved in the next morning, and the patient ate almost all of his breakfast." | 1.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| "Patients who had Japanese Gastric Cancer Association (JGCA) cStage IIIB gastric cancer were enrolled onto this study and received oral S-1 (65 mg/m(2)/day) administration and 50-Gy radiotherapy followed by radical surgery." | 1.38 | Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. ( Hagiike, M; Inoue, T; Kimura, T; Okano, K; Suzuki, Y; Usuki, H; Yachida, S, 2012) |
| " The types and incidence rate of adverse events related to chemotherapy and the results of follow up of the patients were analyzed." | 1.38 | [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012) |
| "We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
| " Thus, TS-1 and CPT-11 combination therapy has been effective for 17 months, suggesting that it is promising for long-term administration and survival to continue it perseveringly." | 1.33 | [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy]. ( Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D, 2006) |
| "We report two metastatic pancreatic cancer patients who showed marked tumor shrinkage following administration of the oral fluorinated pyrimidine anticancer drug, S-1." | 1.33 | [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. ( Ikeda, M; Ueno, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.08) | 18.2507 |
| 2000's | 28 (57.14) | 29.6817 |
| 2010's | 17 (34.69) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 2 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Kobayashi, S | 2 |
| Ueno, M | 1 |
| Ogawa, G | 1 |
| Fukutomi, A | 2 |
| Ikeda, M | 3 |
| Okusaka, T | 3 |
| Sato, T | 2 |
| Ito, Y | 1 |
| Kadota, T | 1 |
| Ioka, T | 1 |
| Sugimori, K | 1 |
| Sata, N | 1 |
| Nakamori, S | 2 |
| Shimizu, K | 1 |
| Mizuno, N | 1 |
| Ishii, H | 1 |
| Furuse, J | 2 |
| Li, J | 1 |
| Xu, R | 1 |
| Xu, J | 1 |
| Denda, T | 2 |
| Ikejiri, K | 1 |
| Shen, L | 1 |
| Toh, Y | 1 |
| Shimada, K | 2 |
| Kato, T | 2 |
| Sakai, K | 1 |
| Yamamoto, M | 1 |
| Mishima, H | 1 |
| Wang, J | 1 |
| Baba, H | 2 |
| Huang, D | 1 |
| Ba, Y | 1 |
| Xiong, J | 1 |
| Xu, N | 1 |
| Yan, Z | 1 |
| Zhuang, Z | 1 |
| Yu, Z | 2 |
| Wan, H | 1 |
| Zhang, Y | 1 |
| Deng, T | 1 |
| Zheng, R | 1 |
| Guo, Z | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 1 |
| Meng, J | 1 |
| Takeda, H | 1 |
| Nishikawa, H | 1 |
| Tsumura, T | 1 |
| Sekikawa, A | 1 |
| Maruo, T | 1 |
| Okabe, Y | 1 |
| Kimura, T | 2 |
| Wakasa, T | 1 |
| Osaki, Y | 1 |
| Tsuburaya, A | 1 |
| Yoshida, K | 2 |
| Kobayashi, M | 2 |
| Yoshino, S | 1 |
| Takahashi, M | 1 |
| Takiguchi, N | 1 |
| Tanabe, K | 2 |
| Takahashi, N | 1 |
| Imamura, H | 2 |
| Tatsumoto, N | 1 |
| Hara, A | 1 |
| Nishikawa, K | 1 |
| Fukushima, R | 1 |
| Nozaki, I | 1 |
| Kojima, H | 1 |
| Miyashita, Y | 1 |
| Oba, K | 1 |
| Buyse, M | 1 |
| Morita, S | 3 |
| Sakamoto, J | 2 |
| Nakai, Y | 1 |
| Isayama, H | 1 |
| Saito, K | 1 |
| Sasaki, T | 2 |
| Takahara, N | 1 |
| Hamada, T | 2 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Yamamoto, K | 1 |
| Mohri, D | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Koike, K | 1 |
| Migita, K | 1 |
| Nashimoto, A | 1 |
| Yabusaki, H | 1 |
| Matsuki, A | 1 |
| Aizawa, M | 1 |
| Honda, G | 1 |
| Kurata, M | 1 |
| Okuda, Y | 1 |
| Sakamoto, K | 1 |
| Karasawa, K | 1 |
| Chang, T | 1 |
| Egawa, N | 1 |
| Kamisawa, T | 1 |
| Omuro, Y | 1 |
| Tsuruta, K | 1 |
| Koizumi, W | 1 |
| Akiya, T | 1 |
| Sato, A | 1 |
| Sakuyama, T | 1 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Mine, T | 1 |
| Yamaguchi, K | 1 |
| Kurihara, M | 1 |
| Sudo, K | 2 |
| Yamaguchi, T | 4 |
| Ishihara, T | 2 |
| Nakamura, K | 3 |
| Hara, T | 1 |
| Tawada, K | 1 |
| Imagumbai, T | 1 |
| Araki, H | 1 |
| Sakai, M | 1 |
| Hatano, K | 1 |
| Kawakami, H | 1 |
| Uno, T | 1 |
| Ito, H | 1 |
| Yokosuka, O | 2 |
| Akaza, H | 1 |
| Ikemoto, I | 1 |
| Namiki, M | 1 |
| Usami, M | 1 |
| Fujimoto, H | 1 |
| Tsukamoto, T | 1 |
| Naito, S | 1 |
| Tsushima, T | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Machida, N | 1 |
| Yamazaki, K | 1 |
| Yasui, H | 2 |
| Taku, K | 1 |
| Onozawa, Y | 1 |
| Ueno, H | 3 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Ohkawa, S | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Shibahara, H | 1 |
| Ito, T | 1 |
| Uematsu, N | 1 |
| Imai, E | 1 |
| Nishimura, D | 1 |
| Inoue, T | 1 |
| Yachida, S | 1 |
| Usuki, H | 1 |
| Hagiike, M | 1 |
| Okano, K | 1 |
| Suzuki, Y | 1 |
| Kunisaki, C | 1 |
| Ono, HA | 1 |
| Hasegawa, S | 1 |
| Oshima, T | 1 |
| Fujii, S | 1 |
| Tokuhisa, M | 1 |
| Izumisawa, Y | 1 |
| Takagawa, R | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Makino, H | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Zhou, Y | 1 |
| Huang, J | 1 |
| Yang, L | 1 |
| Chi, Y | 1 |
| Qu, T | 1 |
| Lü, X | 1 |
| Wang, JW | 1 |
| Nakata, K | 1 |
| Sakata, K | 1 |
| Someya, M | 1 |
| Miura, K | 1 |
| Hayashi, J | 1 |
| Hori, M | 1 |
| Takagi, M | 1 |
| Himi, T | 1 |
| Kondo, A | 1 |
| Hareyama, M | 1 |
| Arai, K | 2 |
| Iwasaki, Y | 2 |
| Kimura, Y | 2 |
| Takahashi, K | 2 |
| Honma, S | 1 |
| Takahashi, T | 1 |
| Shima, Y | 1 |
| Horimi, T | 1 |
| Nishioka, Y | 1 |
| Okabayashi, T | 1 |
| Hamada, M | 1 |
| Ishikawa, T | 1 |
| Shibuya, Y | 1 |
| Sakurama, K | 1 |
| Nishie, M | 1 |
| Iwata, J | 1 |
| Tsuji, A | 1 |
| Saeki, T | 1 |
| Takashima, S | 1 |
| Sano, M | 1 |
| Horikoshi, N | 1 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 1 |
| Kimura, M | 2 |
| Taguchi, T | 2 |
| Johira, H | 1 |
| Yunoki, S | 1 |
| Kawata, N | 1 |
| Watanabe, N | 1 |
| Hachisuka, Y | 1 |
| Uomoto, M | 1 |
| Hatano, H | 1 |
| Sanada, E | 1 |
| Watanabe, R | 1 |
| Ohmori, K | 1 |
| Miyata, N | 1 |
| Nakashima, T | 1 |
| Kuratomi, Y | 1 |
| Masuda, M | 1 |
| Hirakawa, N | 1 |
| Shioyama, Y | 1 |
| Umezaki, T | 1 |
| Komune, S | 1 |
| Takahashi, I | 2 |
| Emi, Y | 1 |
| Kakeji, Y | 2 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Oki, E | 2 |
| Watanabe, M | 1 |
| Maehara, Y | 3 |
| Goto, A | 2 |
| Yamada, Y | 1 |
| Kato, K | 1 |
| Hamaguchi, T | 1 |
| Muro, K | 1 |
| Shimada, Y | 1 |
| Shirao, K | 2 |
| Hashimoto, T | 1 |
| Saze, Z | 1 |
| Matsumoto, H | 2 |
| Yasutome, M | 1 |
| Hiruma, K | 1 |
| Yamashita, Y | 1 |
| Ohtsu, A | 1 |
| Hyodo, I | 1 |
| Wada, Y | 1 |
| Ukon, K | 1 |
| Hihara, J | 1 |
| Egashira, A | 1 |
| Morita, M | 1 |
| Gotoh, M | 1 |
| Kawabe, S | 1 |
| Takiuchi, H | 3 |
| Eguchi, T | 1 |
| Fujii, M | 1 |
| Tsukuda, M | 2 |
| Ishitoya, J | 1 |
| Mikami, Y | 1 |
| Matsuda, H | 1 |
| Katori, H | 1 |
| Horiuchi, C | 1 |
| Yoshida, T | 1 |
| Toth, G | 1 |
| Yumine, K | 1 |
| Kawahara, M | 1 |
| Nakazawa, M | 1 |
| Wataya, H | 1 |
| Ichinose, Y | 1 |
| Morizane, C | 1 |
| Saisho, H | 1 |
| Kawamura, S | 1 |
| Yamagishi, D | 1 |
| Tei, M | 1 |
| Sumi, Y | 1 |
| Shimada, E | 1 |
| Okumura, S | 1 |
| Hirai, T | 1 |
| Hirabayashi, Y | 1 |
| Murakami, H | 1 |
| Higashida, M | 1 |
| Kawabe, Y | 1 |
| Urakami, A | 1 |
| Yamashita, K | 1 |
| Hiratsuka, J | 1 |
| Imajyo, Y | 1 |
| Tsunoda, T | 1 |
| Lee, JL | 1 |
| Kang, HJ | 1 |
| Kang, YK | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Sohn, HJ | 1 |
| Kim, H | 1 |
| Lee, JS | 1 |
| Goto, M | 1 |
| Furukawa, H | 1 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Ishida, H | 1 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
| Nakajo, A | 1 |
| Hokita, S | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Etoh, T | 1 |
| Hamanoue, M | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Aridome, K | 1 |
| Natsugoe, S | 1 |
| Nakano, S | 1 |
| Aikou, T | 1 |
| Shirasaka, T | 1 |
| Shimamoto, Y | 1 |
| Fukushima, M | 1 |
| Inuyama, Y | 1 |
| Kida, A | 1 |
| Kohno, N | 1 |
| Satake, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for oxonic acid and Anorexia
| Article | Year |
|---|---|
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Combination therapy with S-1 and CDDP for head and neck cancer].
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinom | 2006 |
[Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Topics: Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Ad | 2006 |
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, N | 2006 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
29 trials available for oxonic acid and Anorexia
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Respon | 2014 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2015 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; | 2011 |
Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study.
Topics: Adult; Aged; Alanine Transaminase; Androgen Antagonists; Anorexia; Antimetabolites, Antineoplastic; | 2010 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
Topics: Aged; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, | 2013 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini | 2003 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2006 |
[S-1 monotherapy for pancreatic cancer].
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
12 other studies available for oxonic acid and Anorexia
| Article | Year |
|---|---|
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug C | 2021 |
Prominent hypereosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Neo | 2014 |
Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Ch | 2016 |
[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Topics: Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Histamine H1 Antago | 2012 |
Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherap | 2012 |
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
[Two resected cases of advanced gastric cancer with peritoneal dissemination after successful treatment with TS-1 plus low-dose CDDP].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
[Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Sched | 2005 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; D | 2006 |
[Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; | 2006 |